Patent Application
20160067261
The present invention relates to novel combinations of active ingredients for use in the prevention and/or treatment of tumors. The tumors treated by the composition according to the invention overexpress SEC62 gene and overproduce Sec62 protein. The combination of active ingredients comprises at least a SERCA inhibitor and at least a Calmodulin antagonist.
Cancer is one of the most common deadly diseases [1] and the proportion of patients dying due to malignant diseases is increasing every year [2]. For example, lung cancer remains particularly in focus, with five-year survival rates below 20% [3] and therapeutic opportunities are particularly scarce for patients suffering from squamous cell carcinoma (SCC) of the lung [4].
Apoptosis is a process involving programmed cell death or “cellular suicide” and under physiological conditions it occurs after cell surface death receptors are occupied or activated by various genotoxic agents. This process leads to mitochondrial release of cytochrome C, which in turn activates the caspase enzymes that promote apoptosis.
Since apoptosis was first described in 1972 by Kerr et al. much knowledge has been accumulated about this important cellular process. Although a comprehensive understanding of apoptosis at the molecular level and cellular level is yet to be achieved, the knowledge accumulated thus far has led to the realization that because the process is genetically programmed, it may be susceptible to the effects of mutation and, therefore, may be involved in the pathogenesis of a variety of human diseases such as viral infections, autoimmune diseases and cancer. Based on this realization, it has been widely recognized that any therapeutic strategy aimed at specifically triggering apoptosis in diseased cells that suffer from disregulation of apoptosis (e.g. cancer) may deliver potentially promising therapies.
The endoplasmic reticulum (ER) stress response (ESR) consists of a set of adaptive pathways that can be triggered by disparate perturbations of normal ER function, such as accumulation of unfolded proteins, lipid or glycolipid imbalances, or changes in the ionic conditions of the ER lumen. The primary purpose of the ESR is to alleviate stressful disturbance and restore proper ER homeostasis; however, in the case of intense or persistent ER stress, these pathways will trigger programmed cell death/apoptosis. One of the central pro-survival regulators of the ESR is glucose-regulated protein 78 (GRP78/BiP), which has important roles in protein folding and assembly, in targeting misfolded protein for degradation, in ER Ca2+-binding, and in controlling the activation of trans-membrane ER stress sensors. On the other hand, CCAAT/enhancer binding protein homologous transcription factor (CHOP/GADD153) and caspase 4 are critical executioners of the pro-apoptotic arm of the ESR.
The relevance of ER stress to tumor growth and survival is recognized. For example, one effective mode of triggering ER stress response is the inhibition of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA), an intracellular membrane bound enzyme which sequesters cytosolic Ca2+-into its intracellular ER storage compartment. Inhibition of SERCA leads to the release of Ca2+-into the cytoplasm and resulting in activation of severe ER stress, leading to apoptosis.
Several inhibitors of SERCA have been described, to be used as a pro-apoptotic agent for cancer therapy. For instance, the most potent SERCA inhibitor, is the natural product thapsigargin. Another compound that was found to be a SERCA inhibitor is the anti-inflammatory drug celecoxib (Celebrex®) which is an inhibitor of cyclooxygenases-2 (COX-2) (Dannenberg, A J and Subbaramaiah, K, Cancer Cell 2003:4:431). Hydroquinone derivatives are also known as SERCA inhibitor, in particular 2,5-di-tert-buthyhydroquinine (Paula et al. J. bmc 17 (2009) 6613-6619). Paula et al. also reports other known SERCA inhibitors (paragraph 1. Introduction first column last paragraph), for examples cyclopiazonic acid, clotrimazole, thioronium benzene derivatives, tetrabromobisphenol, polyphenols and curcumin are mentioned. SERCA inhibitors are disclosed in US2011318837 and WO2010088450. US2003149995 disclosed a method for screening compounds that affect the activity of SERCA.
Sec 61 complex is a protein complex which has been identified to be a ER Ca2+ leak channel I a membrane protein insertase and a protein translocator. Calmodulin has been identified as limiting Ca(2+) leakage in a Ca(2+)-dependent manner by binding to an IQ motif in the cytosolic aminoterminus of Sec61α.
Calmodulin is a calcium-binding messenger protein produced in all eukaryotic cells. CaM is a multifunctional intermediate messenger protein that transduces calcium signals by binding calcium ions and then modifying its interactions with various target proteins. Calmodulin is a small, highly conserved protein approximately 148 amino acids long (16706 Daltons). It contains four EF-hand motifs, each of which binds a Ca2+ ion. The protein has two approximately symmetrical globular domains (the N- and C-domain), separated by a flexible linker region. Calcium participates in an intracellular signaling system by acting as a diffusible second messenger to the initial stimuli.
Several compounds are known to be Calmodulin antagonist such as ophibolin A, Terodiline hydrochloride, Deltamethrin, trifluoperazine,—Zaldaride maleate, W-13 isomer hydrochloride (CAS #88519-57-7); W5 (CAS #61714-25-8), E6 Berbamine (CAS #73885-53-7), N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide Hydrochloride; Calmidazolium Chloride (CAS 57265-65-3); Fluphenazine-N-2-chloroethane.2HCl (CAS #83016-35-7); CAS #187937-24-2 (CAS #187937-24-2); W-13 Isomer (CAS #79127-24-5), Decyl Analog hydrochloride (CAS #79127-24-5); Phenoxybenzamine (CAS #63-92-3) and several others.
SEC62 has been shown to be a new candidate oncogene that shows significant overexpression and elevated protein content in SCC[5]. Sec62 is an essential protein in yeast, where it is part of the Sec62/Sec63 sub-complex of the SEC complex and acts as a docking site for post-translational protein transport[6]. In mammals, studies have shown that Sec62 is associated with the heterotrimeric Sec61-complex and Sec63[7], and that Sec62 participates in the targeting and translocation of small pre-secretory proteins to the ER[8, 9]. Mammalian Sec62 is also reportedly able to interact with the ribosome, thereby regulating translation[10].
Elevated Sec62 protein content has been shown to be functionally linked to increased cell migration capability [11] and to reduced sensitivity to thapsigargin-induced ER stress [12] both of which are crucially regulated by the cytosolic and ER luminal calcium concentration[13-15].
Previous studies showed that Sec62 depletion by transfection with SEC62 siRNA leads to inhibited cell migration and higher sensitivity to ER stress induced by calcium dysregulation[5, 11, 12]. Therefore, SEC62 gene silencing seemed to provide a promising approach for cancer treatment, especially lung, prostate and thyroid cancer, as such treatment could lead to reduced metastatic outspread of tumor cells as well as a higher cell sensitivity to chemotherapeutics working by ER stress induction.
However, despite intensive studies during the past decades [27-30], using RNA interference for the clinical treatment of human diseases remains unfeasible, mainly because of toxic side effects and major problems in achieving adequate concentrations in the target tissue [31].
There is therefore the need of a pharmaceutical treatment that is able to treat tumor overexpressing Sec62 protein both 1) by inhibiting the cell migration mechanism favored by the overproduction of Sec62 protein and 2) by counteracting the effect that the Sec62 protein overproduction has in reducing the effect of SERCA inhibitor used in the treatment of tumor.
The present inventors have found that the administration of a Calmodulin antagonist in combination with SERCA inhibitor is useful in the treatment of tumors. The tumors are in particular characterized by the overexpression of the SEC62 gene and hence by the overproduction of Sec62 protein.
Namely, the present inventors have found that the combined use of a SERCA inhibitor and a Calmodulin antagonist acts 1) on the inhibition of cell migration and 2) counteracts the reduced efficiency of SERCA inhibitor observed in the treatment of tumor overexpressing SEC62 gene and overproducing Sec62 protein, thereby providing an effective treatment of tumors overexpressing SEC62 gene and hence overproducing Sec62 protein.
SERCA inhibitors such as thapsigargin induce tumoral cell apoptosis by inhibiting SERCA. Namely, the SERCA pump which transports the Ca2+ from the cytosol to the ER is inhibited. As a consequence an elevated concentration of Ca2+ in the cytosol and a lower concentration of Ca2+ in the ER is observed with a consequent induction of apoptosis. Calmodulin antagonist stimulates Ca2+ efflux from ER to cytosol via Sec61 (when the Sec61 channel is open) in the presence of SERCA inhibitors such as thapsigargin. In other words, Calmodulin antagonists are stimulating the Ca2+ leakage from ER to cytosol by acting directly on Calmodulin (and indirectly via Sec61 as Sec61 contains a Calmodulin binding site in the cytosolic N terminus of the mammalian Sec61 alpha subunit).
It has been further observed that when SEC62 is overproduced there is an improvement in sealing of the Sec61 complex and therefore there is a reduction of the Ca2+ efflux from ER to cytosol. It has been observed that therefore an overexpression of SEC62 counteracts the action of the SERCA inhibitors such as thapsigargin in raising the cytosol Ca2+.
It has been surprisingly found by the present inventors that Calmodulin antagonists have also an effect on the Ca2+ leakage from ER to cytosol thereby overcoming the problem of the reduced efficacy of SERCA inhibitors in the presence of SEC62 overexpression. This is particularly surprising because there is no indication in the art that Calmodulin antagonists may counteract the reduction of efflux of Ca2+ from ER to cytosol due to SEC62 overexpression.
The present inventors have found that a strong inhibition of cell migration in different human cancer cells is achieved after Sec62 depletion by transfection with SEC62 siRNA [5, 11]. Moreover, silencing of the SEC62 gene markedly increased the cells' sensitivity to ER stress induced by dysregulation of cellular calcium homeostasis, as shown by the more pronounced growth inhibition of SEC62-depleted cells after treatment with the SERCA inhibitor thapsigargin compared to control cells [5, 12].
These results indicated that Sec62 plays a crucial role in cell migration and ER stress response, particularly in cancer cells. However, the molecular mechanisms these phenomena are based on are not understood and known, since the function of Sec62 is only partially understood even under physiological conditions.
Moreover, although a clear indicium that a Sec62 inhibitor would be useful in inhibiting cell migration and in increasing cell sensitivity to ER stress induced by dysregulation of cellular calcium homeostasis, so far no inhibitors of Sec62 protein are known.
The present inventors have found that Sec62 depletion by siRNA transfection and the treatment of the cells with Calmodulin antagonists resulted in very similar changes of basal cellular calcium level. In addition they have found that the administration of a Calmodulin antagonist results in an increased of cytosolic calcium concentration after thapsigargin treatment (a SERCA inhibitor) (
The present inventors also found that the treatment of different human cancer cells with Calmodulin antagonists leads to the same cellular phenotypes as observed after silencing the SEC62 gene, namely inhibited cell migration and markedly higher cell sensitivity to thapsigargin-induced ER stress (
The present invention also provides, in a further aspect, a method of treating tumor characterized by the overexpression of SEC62 gene and/or by the overproduction of Sec62 protein by administering a combination of pharmaceutically active compounds comprising at least a SERCA inhibitor compound and at least a Calmodulin antagonist compound as described in the present invention.
The present invention is directed to a combination of active ingredients comprising at least a SERCA inhibitor compound in combination with at least a Calmodulin antagonist compound for use in the treatment of a tumor. The tumor is characterized by the overexpression of SEC62 gene and hence by the overproduction of Sec62 protein.
The terms “Calmodulin antagonist” refers to an agent or molecule that inhibits the activity or expression of calmodulin. Calmodulin antagonists can be of synthetic or biological origins. They can be organic, or inorganic molecules, or peptides, antibodies or antisense RNA that inhibit calmodulin. Examples of Calmodulin antagonists of the invention are chemical entities or molecules that can inhibit expression of calmodulin and/or biological activity of calmodulin, including compounds of trifluroperazine (TFP), flurophenazine, perphenazine, and naphthalenesulfonamides, and enantiomers, prodrugs, derivatives and pharmaceutically acceptable salts thereof. A one of ordinary skill in the art will recognize all possible isomers and derivatives such as enantiomers of calmodulin antagonists can also be used as Calmodulin antagonists. “Overexpression of SEC62 gene” is defined as an excessive expression of SEC62 gene. SEC62 gene overexpression may be observed and measured in a tumor histological tissue. The overexpression is measured with respect to the expression of SEC62 gene relative to tumor free histological tissue. The tumor histological tissue and the tumor free histological tissue for comparison of determination of overexpression of SEC62 gene are preferably from the same patient.
The overexpression of SEC62 gene may be measured for example by measuring the SEC62 mRNA, preferably the SEC62 mRNA is from a tumor histological tissue of a patient which is suspected to be affected by a tumor that overexpresses SEC62 gene. The SEC62 mRNA of tumor free histological tissue is measured as well. The quantitative values obtained are than compared to determine whether the SEC62 gene is overexpressed in the tumor histological tissue. Preferably, the tumor histological tissue and the tumor free histological tissue are from the same patient. Preferably, it is considered that SEC62 mRNA is overexpressed when its content in the tumor histological tissue is 1.5 fold with respect to SEC62 mRNA content in tumor free histological tissue, preferably the tumor histological tissue and the tumor free histological tissue are from the same patient. Preferably, the mRNA content is 1.5 fold when measured with real time PCR. Even more, preferably it is considered that SEC62 mRNA is overexpressed when its content in the tumor histological tissue is 2 fold with respect to SEC62 mRNA content in tumor free histological tissue, preferably the tumor histological tissue and the tumor free histological tissue are from the same patient.
Methods of quantitatively measuring the overexpression of a gene are commonly known in the art. For example, Northern blotting, real time PCT (RT-PCR), RNA array or in situ hybridization (ISU) etc. are known methods. These methods are used also for the quantitative measurement of the SEC62 gene overexpression. In particular, according to the present invention, a tumor overexpresses the SEC62 gene if by the analysis of mRNA content in a tumor histological tissue, the analysis reveals a 1.5 fold, preferably a ≧2 fold, increase in SEC62 mRNA expression relative to tumor free histological tissue of the same patient. The preferred method to measure SEC62 mRNA is RT PCR.
In the present invention, alternatively or in combination with the measurement of mRNA, the overproduction of Sec62 protein can be measured. It is known to the skilled person that the overexpression of SEC62 gene in a tumor histological tissue results in an overproduction of the Sec62 protein. Hence either or both the overexpression of SEC62 gene and/or overproduction of Sec62 protein can be measured to determine the tumor to be treated according to the present invention.
“Overproduction of Sec62 protein” is defined as an excessive production of Sec62 protein encoded by the SEC62 gene. Sec62 protein overproduction may be observed and measured in a tumor histological tissue. The overproduction is measured with respect to the production of Sec62 protein relative to tumor free histological tissue. The tumor histological tissue and the tumor free histological tissue for comparison of determination of overproduction of Sec62 protein are preferably from the same patient.
The overproduction of Sec62 protein may be measured for example by measuring the Sec62 protein, preferably Sec62 protein is from a tumor histological tissue of a patient which is suspected to be affected by a tumor that overproduce Sec62 protein. Sec62 protein of tumor free histological tissue is measured as well. The quantitative values obtained are than compared to determine whether the Sec62 protein is overproduced in the tumor histological tissue. Preferably, the tumor histological tissue and the tumor free histological tissue are from the same patient. Preferably, it is considered that Sec62 protein is overproduced when its content in the tumor histological tissue is ≧1.5 fold, preferably a ≧2 fold, with respect to the Sec62 protein content in tumor free histological tissue, preferably the tumor histological tissue and the tumor free histological tissue are from the same patient. Preferably the protein content is measured with western blot.
Methods of quantitatively measuring the overproduction of a protein are commonly known in the art. For example western blot, histochemistry method such as immunohistochemistry or protein arrays etc. methods can be used. These methods are used also for the quantitative measurement of the Sec62 protein overproduction. In particular, according to the present invention, a tumor overproduces Sec62 protein if by the analysis of Sec62 protein content in a tumor histological tissue, the analysis reveals a ≧1.5 fold, preferably a ≧2 fold increase in Sec62 protein relative to tumor free histological tissue of the same patient. The preferred method to measure Sec62 protein is western blot.
Hence, the present invention is directed to a SERCA inhibitor in combination with Calmodulin antagonist for use in the treatment of tumor wherein the tumor is defined as a tumor that overexpresses SEC62 gene and/or a tumor that overproduces sec62 protein. The skilled person understands that the overproduction of Sec62 protein is the result of overexpression of SEC62 gene.
Hence, the present invention is directed to a SERCA inhibitor in combination with Calmodulin antagonist for use in the treatment of tumor wherein the tumor is defined as a tumor that overexpresses SEC62 gene or a tumor that overproduces Sec62 protein and wherein the overexpression of SEC62 gene is measured by the analysis of mRNA content in a tumor histological tissue and the analysis reveals a more than 1.5 fold increase in Sec62 expression relative to tumor free histological tissue preferably of the same patient and/or wherein the overproduction of Sec62 protein is measured by the analysis of Sec62 protein level in a tumor cell and the analysis reveal a more than 1.5 fold increase in Sec62 protein level relative to tumor free tissue preferably of the same patient.
In a preferred embodiment, the overexpression of SEC62 gene refers to more than 1.5 fold increase in SEC62 expression relative to tumor free histological tissue of the same patient when measuring SEC62 mRNA content in a tumor cell. In another preferred embodiment, the overproduction of Sec 62 protein refers to more than 1.5 fold increase in Sec62 protein level relative to tumor free tissue of the same patient when measuring the Sec62 protein level in a tumor cell.
Hence, the present invention is directed to a combination of at least SERCA inhibitor and at least a Calmodulin antagonist for use according to the present invention wherein the SEC62 mRNA is measured with RT-PCR or with in situ hybridization or with RNA array and the Sec62 protein is measured with Western Blot, histochemistry method or protein arrays.
The SERCA inhibitor in combination with a Calmodulin antagonist for use according to the present invention is any compound suitable for inhibiting the SERCA activity. SERCA inhibitors are known in the art. The SERCA inhibitor compound according to the present invention may be selected from sesquiterpene lactones and derivative thereof (compounds built from 3 isoprene units and containing a lactone ring), such as thapsigargin and prodrug thereof such as 8-O-(12Aminododecanoyl)-8-0 debutanoylthapsigargin (G202) and the peptide prodrug L12ADT and, artemisinin; hydroquinone based compounds such as 2,5-di(tert-butyl)hydroquinone (BHQ); 1,3-dibromo-2,4,6-tris(methyl-isothio-uronium)benzene, celecoxib cyclopiazonic acid; clotrimazole, thioronium benzene derivatives, tetrabromobisphenol, polyphenols and curcumin.
Thapsigargin and the prodrug L12ADT have formulae
Thapsigargin and prodrug thereof, in particular G202 and L12ADT prodrug are preferred SERCA inhibitors according to the invention. G202 and L12ADT are known in the art and have been described, for example, in Denmeade et al 2012 and Denmeade et al 2003.
The Calmodulin antagonist according the present invention is any compound suitable for antagonizing Calmodulin. Calmodulin antagonists are known in the art. A Calmodulin antagonist according to the invention may be selected from trifluoperazine, Ophobolin A, the compound of formula
the compound of formula
(also known as CGS 9343B and having CAS number: CAS 109826-27-9), Zaldaride maleate,
the compound of formula
(also known as W-13 isomer hydrochloride (CAS #88519-57-7));
the compound of formula
the compound of formula
(also known as E6 Berbamine (CAS #73885-53-7)), N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide Hydrochloride; Calmidazolium Chloride (CAS 57265-65-3); the compound of formula
Fluphenazine-N-2-chloroethane.2HCl (CAS #83016-35-7),
the compound of formula
the compound of formula
the compound of formula
Preferred Calmodulin antagonists according to the invention are trifluoperazine and Ophiobolin A.
Calmodulin antagonists may be, but are not limited to, calmidazolium chloride (CAS No. 57265-65-3), E6 Berbamine (CAS No. 73885-53-7) fluphenazine-N-2-chloroethane.2HCl (CAS No. 83016-35-7), J-8 hydrochloride (CAS No. 187937-24-2), ophiobolin B (CAS No. 5601-74-1), W-5, hydrochloride (CAS No. 61714-25-8), W-5 isomer hydrochloride (CAS No. 35517-14-7), W-7 hydrochloride (CAS No. 61714-27-0), W-7 isomer hydrochloride (CAS No. 69762-85-2), W-13. hydrochloride (CAS No. 88519-57-7) W-13 isomer hydrochloride (CAS No. 88519-57-7), W-13 isomer, decyl analog hydrochloride (CAS No. 79127-24-5), chlorpromazine hydrochloride (CAS No. 69-09-0), Compound 48/80 trihydrochloride (CAS No. 94724-12-6), trifluoperazine dihydrochloride (CAS No. 440-17-5), trifluoperazine (CAS No. 117-89-5), CGS 9343B (CAS No. 109826-27-9), W-12, hydrochloride (CAS No. 89108-46-3), ophiobolin A (CAS No. 4611-05-6), HBC (Jung et al. 2010), DY-9760e (CAS No. 162496-41-5), phenoxybenzamine hydrochloride (CAS No. 63-92-3), mastoparan (CAS No. 72093-21-1), mastoparan (Polistes) (CAS No. 74129-19-4), mastoparan X (CAS No. 72093-22-2), mastoparan-7 (CAS No. 145854-59-7), CALP2 (CAS No. 261969-04-4), camstatin (CAS No. 1002295-95-5), and suramin (CAS No. 129-46-4). Other Calmodulin antagonists known in the art such as members of phenothiazine family, Ca2+ channel blockers nimodipine and YS-035 as described in WO2013138101 can be used.
SERCA inhibitors are known in the art. For example, Michelangeli et al. 2011 discloses 1,3-dibromo-2,4,6-tris(methylisothiouronium)benzene (Br2-TITU), 2APB, 3,6-dihydroxyflavone, 4-chloro-m-cresol, alisol B, BHQ, bisphenol, bisphenol A, calmidazolium, chlorpromazine, curcumin, cyclopiazonic acid, A, DES, fluphenazine, galangin, ivermectin, mastoparan, nonylphenol, orthovanadate, paxilline, peptide M391, quercitin, eapamycin, sHA 14-1, TBBPA, and thapsigargin as compounds that act as SERCA inhibitors. Other examples of SERCA inhibitors include, but are not limited to, G-115 (U.S. Pat. No. 7,635,682), ruthenium red (Charuk et al. 1990) CXL017 (Bleeker et al. 2013), Saikosaponin-d (Wong et al. 2013), and artemisinins (Eckstein-Ludwig et al. 2003). Further examples are disclosed in US2010087374 and WO2010088450.
The present inventors have identified a group of tumors, namely the tumors that overexpress SEC62 gene and hence overproduce Sec62 protein. The tumors treated by the combinations of the inventions are tumors that overexpress SEC62 gene and hence overproduce Sec62 protein. Said tumors are for examples non-small lung cell lung cancer, tyroid cancer, prostate cancer, head and neck cancer, multiple myeloma and other. The present inventors have found that there are tumors of the same kind that do or do not overexpress SEC62 gene and hence do or do not overproduce Sec62 protein. For example, it has been seen by the present inventors that only about half of the prostate cancer shown an overexpression of SEC62 gene (Greiner et al. The prostate 71:1074-1083 (2011). Hence, the present “prostate cancer” as used herein is not any prostate cancer but a subgroup of prostate cancer, specifically the prostate cancer that overexpresses SEC62 gene and hence overproduces Sec62 protein. The same applies to other tumors. Hence, the present invention is directed to the treatment of a subgroup of lung cancer, a subgroup of tyroid cancer, a subgroup of prostate cancer, a subgroup of head and neck cancer, a subgroup of multiple myeloma and a subgroup of tumors wherein said subgroup of the specified tumor overexpresses SEC62 gene and hence overproduces Sec62 protein.
Tumors in which overexpression of SEC62 gene or overproduction of Sec62 has been observed include, but are not limited to, prostate carcinoma, small cell lung carcinoma, large-cell lung carcinoma, malignant mesothelioma, lobular breast carcinoma, tubular breast carcinoma, ductal breast carcinoma, medullary breast carcinoma, gallbladder adenocarcinoma, follicular thyroid, carcinoma, papillary thyroid carcinoma (Greiner et al. 2011 in Int J Cancer) squamous cell lung carcinoma, lung adenocarcinoma (Greiner et al. 2011 in Int J Cancer and Linxweiler et al. 2012), advanced nasopharyngeal carcinoma (Sheu et al. 2009), vulva carcinoma (Stoltzfus et al. 2005) head and neck squamous cell carcinoma (Singh et al. 2002 and Singh et al. 2001) as well as breast cancer, esophageal cancer, myeloma and colorectal cancer (Hagerstrand et al. 2013). Other tumors may be those from thyroid carcinoma, ovarian cancer, breast cancer, cervical cancer, pancreatic cancer, uterine corpus endometrial cancer, stomach adenocarcinoma cancer, hepatocellular carcinoma, or glioblastoma. The present compound is particularly useful for treating such tumors accompanied by SEC62 overexpression or Sec62 overproduction.
In an embodiment, the SERCA inhibitor in combination with a Calmodulin antagonist for use in the treatment of tumor wherein the tumors are as defined according to the present invention wherein the SERCA inhibitor and the Calmodulin antagonist are administered simultaneously or sequentially or separately.
By simultaneous therapeutic use, within the meaning of the present invention is meant an administration of at least a SERCA inhibitor and a Calmodulin antagonist by the same route and at the same time or at approximately the same time.
By separate use, within the meaning of the present invention is meant in particular an administration of at least a SERCA inhibitor and a Calmodulin antagonist at the same time or at substantially the same time by different routes.
By sequential therapeutic use is meant administration of at least a SERCA inhibitor and a Calmodulin antagonist at different times, the administration route being identical or different. More particularly by an administration method is meant a method according to which the whole administration of one of the active ingredients is carried out before administration of the other or others commences. It is thus possible to administer one of the active ingredients 1-3 hours before administering the other active ingredient or ingredients. Preferably 1 hour. There is no simultaneous treatment in this case.
Hence, the SERCA inhibitor in combination with a Calmodulin antagonist for use according to the present invention are administered sequentially within an interval of 1 to 3 hours preferably, 1 hour.
The pharmaceutical formulation of a combination or combined preparation of the invention is dependent upon the administration route, in accordance with the usual practice in the field.
In a combination or combined preparation of the invention, said at least one SERCA inhibitor and a Calmodulin antagonist can e.g., be formulated in a form suitable for parenteral, trans-mucosal, enteral or topical administration, advantageously for intravenous administration. Said at least one SERCA inhibitor and a Calmodulin antagonist may be formulated for different administration routes for example, in a form suitable for parenteral administration for said at least one SERCA Inhibitor or a Calmodulin antagonist, and in a form suitable for trans-mucosal administration for said at least SERCA Inhibitor or a Calmodulin antagonist. Alternatively, they can be both formulated for the same administration route (for example, both in a form suitable for parenteral/intravenous administration).
A preferred parenteral administration is the intravenous administration.
In an embodiment of the invention, a combination or combined preparation of the invention is formulated in a form suitable for, or is intended for systemic or intra-tumoral administration.
The determination of the dose regimen of said at least SERCA Inhibitor and a Calmodulin antagonist inhibitor is determined by the person of ordinary skill in the art so as to achieve the desired effect, notably the treatment of the tumor of the invention.
The dose regimen, more particularly the dose amount (or dose per administration) of said at least one SERCA inhibitor and a Calmodulin antagonist, is advantageously such that said at least a SERCA inhibitor and a Calmodulin antagonist exert an advantageous effect, in the treatment of tumors according to the invention. The effect may also be intended as due to the counteraction of the Calmodulin antagonist on the reduce efflux of Ca2+ from ER to cytosol due to Sec62 protein overproduction. As already explained, the overproduction of Sec62 protein reduces the efficiency of SERCA inhibitors in the treatment of those tumors that overexpress SEC62 gene. In addition, the Sec62 protein overproduction stimulates cell migration which is an undesirable effect in tumor treatment. Cell migration is inhibited by the Calmodulin antagonist, thereby leading to an improved treatment of the tumors of the invention.
For example, at a fixed dose amount of said at least SERCA inhibitor, the dose amount of said at least one Calmodulin antagonist can be increased up to the point where said advantageous effect is observed and/or the frequency of administration of each dose of said at least one Calmodulin antagonist can be increased up to said advantageous point. Hence, the dose of the Calmodulin antagonist can be increased till no negative effect of the overproduction of Sec62 protein is observed on the SERCA inhibitor and an effect on the inhibition of tumor cell migration is observed.
For example, the dose regimen, more particularly the dose amount of said at least one SERCA inhibitor and a Calmodulin antagonist is such that said at least one Calmodulin antagonist increases the sensitivity of the tumor cells to the SERCA inhibition induced by the SERCA inhibitor. Objective solid tumor response can be measured or monitored e.g., using the Response Evaluation Criteria in Solid Tumors (RECIST); cf. Therrasse et al. 2000, and Eisenhauer et al. 2009. The dose regimen of said at least one SERCA inhibitor and/or of said at least one Calmodulin antagonist (dose amount at each administration and/or frequency of administration of each dose) should also be adjusted so as to limit the induced toxicity to a level that is acceptable for the health of the subject(s).
The SERCA inhibitor in combination with a Calmodulin antagonist for use according to the present invention may be also combination wherein the SERCA inhibitor and the Calmodulin antagonist are formulated together in the same pharmaceutical composition.
In an embodiment, the SERCA inhibitor and the Calmodulin antagonist in combination for use according to the present invention are administered orally, intravenously, intramuscularly.
Preferred combinations of active ingredients according to the invention are those comprising thapsigargin or a prodrug thereof such as 8-O-(12Aminododecanoyl)-8-O debutanoylthapsigargin (G202) and the peptide prodrug L12ADT as SERCA inhibitor and trifluoperazine or Ophobolin A as Calmodulin antagonist.
It must be noted that as used herein, the singular forms “a”, “an”, and “the”, include plural references unless the context clearly indicates otherwise. Thus, for example, reference to “a reagent” includes one or more of such different reagents and reference to “the method” includes reference to equivalent steps and methods known to those of ordinary skill in the art that could be modified or substituted for the methods described herein.
All publications and patents cited in this disclosure are incorporated by reference in their entirety. To the extent the material incorporated by reference contradicts or is inconsistent with this specification, the specification will supersede any such material.
Unless otherwise indicated, the term “at least” preceding a series of elements is to be understood to refer to every element in the series. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the present invention.
Throughout this specification and the claims which follow or items, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integer or step. When used herein the term “comprising” can be substituted with the term “containing” or sometimes when used herein with the term “having”.
When used herein “consisting of” excludes any element, step, or ingredient not specified in the claim element. When used herein, “consisting essentially of” does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim.
In each instance herein any of the terms “comprising”, “consisting essentially of” and “consisting of” may be replaced with either of the other two terms.
Several documents are cited throughout the text of this specification. Each of the documents cited herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc.), whether supra or infra, are hereby incorporated by reference in their entirety. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
As described herein, “preferred embodiment” means “preferred embodiment of the present invention”. Likewise, as described herein, “various embodiments” and “another embodiment” means “various embodiments of the present invention” and “another embodiment of the present invention”, respectively.
The influence of Sec62 protein content in lung cancer on survival of patients was analyzed by the Kaplan-Meier method and a log-rank-test. To elucidate the underlying pathophysiological functions of Sec62, calcium imaging techniques, real time cell analysis and cell migration assays were used.
Furthermore, the effects of treatment with Calmodulin antagonists triflouoperazine (TFP) and ophiobolin A on cellular calcium homeostasis, cell growth and cell migration were compared to siRNA mediated Sec62 depletion or expression of a mutated SEC62 variant in human cell culture. BIAcore analysis was employed to study the calcium-sensitive interaction of Sec62 with the Sec61 complex.
Results
Sec62 protein overproduction has a significant negative effect on patients' survival in lung cancer. Therefore, Sec62 protein has been postulated to be an interesting therapeutic target. On the molecular level, a regulatory function of Sec62 protein on the major calcium leak channel of the endoplasmic reticulum, the Sec61-channel, was postulated by the observation of a direct and calcium sensitive interaction. A calcium binding motive in Sec62 protein is shown to be essential for its molecular function. It has been found by the present inventors that treatment of cells with Calmodulin antagonists mimicked Sec62 depletion phenotypes, inhibited cell migration and rendered the cells sensitive for thapsigargin (SERCA inhibitor) treatment.
Hence the present inventors have found that Sec62 protein function as a modulator of Ca2+-Calmodulin binding to the major ER calcium leak channel. Furthermore the present inventors have found and shown that Calmodulin antagonists have a similar effect on tumor cells compared to SEC62 gene silencing. Thus targeting Sec62 overproducing tumors using Calmodulin antagonists in combination with SERCA inhibitors (e.g. thapsigargin) is novel personalized therapeutic strategy for the treatment of tumors that overexpress SEC62 gene and overproduce Sec62 protein.
Detection of SEC62 amplification and overexpression in non-small cell lung cancer (NSCLC) has been disclosed in reference [5]. The present inventors have tested whether a lower Sec62 protein content in cancer tissue was associated with longer patient survival, i.e., if Sec62 can indeed serve as a prognostic marker.
Using the Kaplan-Meier method and log-rank test, the inventors investigated the association between the rSec62 values of 70 NSCLC patients that were mentioned in the previous publication[5] with these patients' survival starting from the date of diagnosis.
Patients were divided into two groups based on their rSec62 value, applying thresholds of 2.1 (all patients,
Survival analyses were visualized using Kaplan-Meier diagrams. Using the log-rank-test, the inventors observed a highly significant survival benefit in the low rSec62 group compared to the high rSec62 group, among all lung cancer patients as well as for SCC patients separately; however the survival of AC patients showed only a tendency but no significant dependency on rSec62 values (P=0.001 for all NSCLC patients, P=0.001 for SCC patients, P=0.054 for AC patients).
Subsumed these data indicate the high clinical relevance of the Sec62 protein level majorly for SCC of the lung which is even more important in the context of the fact that the increased Sec62 protein level also protects tumor cells from the potential therapeutic use of thapsigargin[12].
SEC62 silencing is one possibility to overcome the protective effect of SEC62 overexpression against thapsigargin, as SEC62 silencing leads to an increase in cytosolic calcium concentration, as well as enhanced calcium leakage from the ER in combination with thapsigargin, as was shown by live cell calcium imaging[12]. The present inventors have also discovered a crucial influence of Calmodulin on ER calcium homeostasis, namely limiting ER calcium leakage by calcium-dependent binding to the Sec61-complex [16, 17]. As the therapeutic use of siRNAs still suffers from the problem of delivery, the present inventors considered whether the Sec62 protein regulates Calmodulin binding to the Sec61-complex, or if it may itself modulate the Sec61 complex as this would allow the therapeutic use of Calmodulin antagonists to counter the increased Sec62 protein level. To do this, the inventors have examined the effects on calcium homeostasis following treatment with the Calmodulin antagonists trifluoperazine (TFP) and ophiobolin A in comparison to the effects of siRNA mediated Sec62 depletion.
All the three treatments resulted in a comparable increase of cytosolic calcium in the absence of and in combination with thapsigargin treatment. These results strongly prove that that a similar molecular mechanism leads to deregulation of cellular calcium homeostasis after SEC62 silencing and after treatment with Calmodulin antagonists.
Therefore, the inventors next considered whether the effect of Sec62 on ER Ca2+ leakage could be linked to the Ca2+ permeable Sec61 complex as it was shown before for the effects of TFP or ophiobolin A[16, 18]. To address this question, the inventors treated HeLa cells for 96 h with SEC62 siRNA, SEC61A1 siRNA, SEC62 plus SEC61A1 siRNA, or a negative-control siRNA. The results of live cell Ca2+ imaging experiments for cells with SEC61A1 or SEC62 siRNA confirmed the previous observations (
To directly demonstrate the putative interaction of Sec62 with Sec61a and to identify the Sec62 binding site, the present inventors have carried out peptide binding experiments. Peptide spots that correspond to human Sec61a1 were synthesized on cellulose membranes. The peptides consisted of 12 amino acid residues with an overlap of 10 residues with adjacent peptides and were incubated with the C-terminal cytosolic domain of the double-spanning membrane protein Sec62.
The C-terminal domain of Sec62 (Sec62C) preferentially bound to the N-terminal peptide of Sec61a (amino acid residues 1-16) (
The inventors previously showed that Sec62 depletion inhibits the spread of metastatic tumor cells and raises the cells' sensitivity to calcium-driven ER stress. By introducing the mutation D308A in the predicted calcium-binding motif within the C-terminus of Sec62, the inventors confirmed the function of Sec62 in regulating ER calcium homeostasis (
To study the influence of TFP and ophiobolin A on cellular processes other than calcium homeostasis, the inventors first analyzed the proliferation of PC3 (non-overproducing prostate cancer cell line) and HeLa cells in the presence of these two Calmodulin antagonists. The inventors also analyzed HEK293 cells (non overproducing cell line) with respect to their TFP sensitivity. PC3 and HeLa cells showed the same sensitivity to ophiobolin A; both cell lines showed normal growth behavior up to a concentration of 500 nM, whereas higher concentrations significantly inhibited cell growth (
Next, the inventors wanted to know if a strongly reduced migration potential and increased sensitivity to thapsigargin-induced ER stress could also be caused by TFP or ophiobolin A treatment. First, the inventors studied cell migration of PC3 and HeLa cells in the presence of increasing amounts of ophiobolin A or TFP. The inventors found dose-dependently reduced cell migration for both cell lines with both substances (
Since Sec62 depletion by siRNA transfection alone was sufficient to block cell migration in the previous experiments [11], the inventors next asked if SEC62 overexpression would rescue the migration defect of ophiobolin A or TFP-treated cells. HEK293 cells were used, which did not migrate in the assay without treatment but could be stimulated to migration by addition of 12-O-tetradecanoylphorbol 13-acetate (TPA), a drug that down-regulates agonist-driven calcium release from the ER [19] and stimulates cell migration[20, 21]. The inventors compared HEK293 cells stably transfected with a pIRES-GFP vector (control plasmid) with HEK293 cells stably overexpressing a plasmid-encoded SEC62 gene (pSEC62-IRES-GPF). Migration of un-transfected and control-transfected HEK293 cells were completely inhibited by 100 nM ophiobolin A or 8 μM TFP (
Next the inventors wanted to investigate whether the observations regarding cell migration were also true for the second phenotype—increased cell sensitivity to thapsigargin treatment after SEC62 silencing. The inventors first transfected PC3 cells with control siRNA or siRNA specifically directed against the SEC62 mRNA, followed by treatment with 10 nM thapsigargin either in the presence of 8 μM TFP or 0.1% DMSO (solvent control) and observed cell growth. Again, this experiment showed higher sensitivity to thapsigargin treatment in Sec62-depleted cells, and a similar behavior of control siRNA-transfected cells after TFP treatment, indicated by a slightly weaker decline in the growth rate (
The examples were performed using the following cell culture and tissue samples
Cell lines PC3 (DSMZ no. ACC 465), HeLa (DSMZ no. ACC 57) and HEK293 (DSMZ no. ACC 305) were cultured at 37° C. in DMEM medium (Gibco Invitrogene, Karlsruhe, Germany) containing 10% FBS (Biochrom, Berlin, Germany) and 1% penicillin/streptomycin (PAA, Pasching, Austria), in a humidified environment with 5% CO2. We used stably transfected HEK293 cell lines expressing plasmid-encoded wild-type SEC62 gene (pSEC62-IRES-GPF) or an empty control plasmid (pIRES-GPF) as already published.[5] A plasmid encoding a D308A point mutation of SEC62 (psec62D308A-IRES-GPF) was generated using the QuikChange Site-Directed Mutagenesis Kit (Stratagene) following the manufacturer's instructions. The plasmid was sequenced to confirm the point mutation. Also for this plasmid a stably transfected cell line was generated by transfecting 2.4×105 HEK293 cells in a 6-well plate using FuGeneHD Reagent (Qiagen) following the manufacturer's instruction. After 72 hours, medium was changed to normal culture medium containing 1% G418 and cells were further cultured until a selection was reached. Then cells were harvested, diluted to a density of 1 cell per 100 μl and 100 μl per well was seeded to a 96-well plate in medium containing 1% G418. Clones originated from a single cell were selected and analyzed with respect to Sec62 protein content. Further cultivation and all experiments using stably transfected cell lines were performed in normal growth medium containing 1% G418.
The Sec62 concentration in cancerous and tumor-free lung tissue of 70 NSCLC patients with pathologically confirmed AC or SCC were measured by western blot using β-actin as a loading control in the previous study and calculated a relative Sec62 (rSec62=[Sec62tumor/b-actintumor]/[Sec62tumor-free/b-actintumor-free]) protein content elevation in the tumor.[5] Either all patients (n=70) or the subgroups of AC (n=35) or SCC (n=35) patients were divided into two groups based on the mean rSec62 value of the respective group, and survival analyses were performed using the Kaplan-Meier method and log-rank-test.
Protein Quantification in Cells by Western Blot
Proteins were quantified from the lysate of 2×105 cultured cells by western blot analysis. An affinity-purified polyclonal rabbit anti-peptide antibody directed against the COOH terminus of human Sec62, a polyclonal rabbit anti-BiP antibody, a polyclonal rabbit anti-peptide antibody directed against the C-terminus of human Sec61a, and a polyclonal anti-β-actin antibody (Cell Signaling Biotechnology, FL-335) were used. The primary antibodies were visualized with an ECL™ Plex goat anti-rabbit IgG-Cy5 or ECL™ Plex goat anti-mouse IgG-Cy3 conjugate (GE Healthcare, Munich, Germany) and the Typhoon-Trio imaging system (GE Healthcare) in combination with the Image Quant TL software 7.0 (GE Healthcare). We determined the ratio of Sec62, Sec61a, or BiP to β-actin.
Silencing of Gene Expression by siRNA
For gene silencing, 5.4×105 cells were seeded in 6-cm dishes, in normal culture medium. The cells were transfected with SEC62-UTR siRNA (CGUAAAGUGUAUUCUGUACtt; Ambion, TX, USA) (SEQ ID NO: 1), SEC62 siRNA (GGCUGUGGCCAAGUAUCUUtt; Ambion) (SEQ ID NO: 2), SEC61A1 siRNA (GGAAUUUGCCUGCUAAUCAtt, Qiagen, Hilden, Germany) (SEQ ID NO: 3), or control siRNA (AllStars Neg. Control siRNA; Qiagen) using HiPerFect Reagent (Qiagen) following the manufacturer's instructions. After 24 h, the medium was changed and the cells were transfected a second time. Silencing efficiency was evaluated by western blot analysis. The maximum silencing effect was seen 72 h (SEC62 siRNAs) or 96 h (SEC61A1 siRNA) after the first transfection.
Real-Time Cell Proliferation Analysis
The xCELLigence SP system (Roche Diagnostics GmbH, Mannheim, Germany) was used for the real-time analysis of cell proliferation. In this system, 1.0×104 or 2.0×104 either stably transfected HEK293 cell lines as described above or untreated HEK293-, PC3- or HeLa-cells or PC3-cells pretreated with siRNA in 6-cm dishes as described above were seeded into a 96-well e-plate (Roche Diagnostics GmbH) according to the manufacturer's instructions. The seeding of siRNA pretreated cells occurred 24 hr after the second transfection. If cells were treated with thapsigargin, TFP or ophiobolin A, this occurred at least 4 hr after seeding onto the plates. Cell proliferation was monitored for 53-96 h, and data evaluated with RTCA 1.2 software (Roche Diagnostics GmbH).
Peptide Spot Binding Assay
13 Peptides scanning the N-terminus of human Sec61a were synthesized on cellulose membranes via carboxy-terminal attachment as described.[16, 45] The peptides consisted of 12 amino-acid residues with an overlap of 10 residues with adjacent peptides and were incubated with Sec62-C-6His (1 μM) purified from E. coli as described previously[10] in binding buffer (30 mM Tris-HCl pH 7.4, 170 mM NaCl, 6.4 mM KCl, 5% sucrose, 0.05% Tween20). After washing the membranes two times with binding buffer bound protein was detected using anti-His-POD coupled antibody (1:1000, Qiagen), again washed two times with binding buffer, followed by incubation with ECL (GE Healthcare) and subsequently visualized with a lumi-imaging system (Roche Diagnostics GmbH).
Surface Plasmon Resonance Spectroscopy
Surface plasmon resonance spectroscopy was performed in a BIAlite upgrade system (BIACORE). Peptides representing the N-terminus of Sec61 (AIKFLEVIKPFC) (SEQ ID NO: 4) in the measuring cell or the N-terminus of TRAM (VLSHEFELQNGADC) (SEQ ID NO: 5) in the control cell were immobilized on a CM5 sensor chip using ligand-thiol-coupling according to the manufacturer's protocol. Measurements were performed at a flow rate of 10 μl/min in 10 mM HEPES-KOH, pH 7.4, 150 mM NaCl, 2 mM MgCl, 6.4 mM KCl and 0.005% surfactant (buffer minus Ca2+). For interaction analysis Sec62-C-6His (1 μM) purified from E. coli as described previously[10] in the buffer minus Ca2+ or in the same buffer containing 2 mM Ca2+ or the calcium containing buffer alone was passed over the chip. Response units are shown as a difference between measuring- and control cell. The analysis was carried out by employing BIA evaluation software version 3.1 (BIACORE) using 1:1 binding models and mass transfer.
Migration Potential Analysis
Migration was tested with the BD Falcon FluoroBlok system (BD, NJ, USA) in 24-well inserts. A total of 2.5×104 either stably transfected HEK293 cell lines as described above or untreated PC3- or HeLa-cells were loaded into this system in normal medium containing 0.5% FBS. If DMSO, TFP or ophiobolin A was used these drugs were added to the top and to the bottom chamber in the concentrations given in the figure. The inserts were placed in medium with 10% FBS as a chemo-attractant. After 72 h, the cells were fixed with methanol and stained with DAPI, and migrating cells were analyzed on the backside of the membrane by fluorescence microscopy.
Live-Cell Calcium Imaging
For live-cell calcium imaging, HeLa cells were loaded with 4 mM FURA-2 AM (Molecular Probes, Eugene, Oreg., USA) in DMEM for 45 min at room temperature as previously described.[46, 47] Two washes were performed with a calcium-free buffer (140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 0.5 mM EGTA, and 10 mM glucose in 10 mM HEPES-KOH at pH 7.35) and the experiments were carried out in the same solution. A ratiometric measurement was performed for 3 min to determine the initial cytosolic [Ca2+], then thapsigargin (1 μM) was added and the measurement was continued. Cells differently pretreated as described in the text were compared with respect to initial cytosolic [Ca2+] and thapsigargin-induced changes in cytosolic [Ca2+]. Data were collected on an iMIC microscope and the polychromator V (Till Photonics, Graefelfing, Germany) by alternately exciting at 340 and 380 nm, and measuring the emitted fluorescence at 510 nm (dichroic, DCLP410; emitter filter LP470; Till Photonics). Images containing 50-60 cells/frame were sampled every 3 sec. FURA-2 signals were recorded as a F340/F380 ratio, where F340 and F380 correspond to the background-subtracted fluorescence intensities at 340 and 380 nm, respectively. Cytosolic [Ca2+] was estimated from ratio measurements using an established calibration nnethod.[48] Data were analyzed using Excel 2007 and Origin 6.1
| Number | Date | Country | Kind |
|---|---|---|---|
| 13164706.7 | Apr 2013 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2014/058074 | 4/22/2014 | WO | 00 |
